Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 3
2002 3
2003 5
2004 1
2005 5
2006 7
2007 8
2008 17
2009 24
2010 24
2011 21
2012 24
2013 47
2014 33
2015 23
2016 39
2017 35
2018 39
2019 47
2020 36
2021 37
2022 29
2023 26
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Results by year

Filters applied: . Clear all
Page 1
Cangrelor.
Awosika AO, Patel P. Awosika AO, et al. 2023 Jul 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 37603660 Free Books & Documents.
Cangrelor, a potent intravenous antiplatelet agent, has been approved by the U.S. ...This therapeutic review aims to provide an in-depth analysis of cangrelor, encompassing its indications, FDA approval, off-label uses, mechanism of action, pharmacokinetics, …
Cangrelor, a potent intravenous antiplatelet agent, has been approved by the U.S. ...This therapeutic review aims to provide a …
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ; BRIDGE Investigators. Angiolillo DJ, et al. JAMA. 2012 Jan 18;307(3):265-74. doi: 10.1001/jama.2011.2002. JAMA. 2012. PMID: 22253393 Free PMC article. Clinical Trial.
Interventions Thienopyridines were stopped and patients were administered cangrelor or placebo for at least 48 hours, which was discontinued 1 to 6 hours before CABG surgery. ...There were no significant differences in major bleeding prior to CABG surgery, although minor b …
Interventions Thienopyridines were stopped and patients were administered cangrelor or placebo for at least 48 hours, which was disco …
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group. Roffi M, et al. Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29. Eur Heart J. 2016. PMID: 26320110 Free article. No abstract available.
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. De Luca L, et al. J Am Heart Assoc. 2021 Jul 6;10(13):e022125. doi: 10.1161/JAHA.121.022125. Epub 2021 Jul 2. J Am Heart Assoc. 2021. PMID: 34212768 Free PMC article. Review.
Cangrelor is the only currently available intravenous platelet P2Y(12) receptor inhibitor. ...These observations underscore the need to fully examine the safety and efficacy of cangrelor in postregistration studies. There are several ongoing and planned studies eval …
Cangrelor is the only currently available intravenous platelet P2Y(12) receptor inhibitor. ...These observations underscore the need …
Cangrelor AstraZeneca.
Chattaraj SC. Chattaraj SC. Curr Opin Investig Drugs. 2001 Feb;2(2):250-5. Curr Opin Investig Drugs. 2001. PMID: 11816839 Review.
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. ...AstraZeneca is also developing derivatives of …
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential t …
Cangrelor for the treatment of patients with Arterial Thrombosis.
Tantry U, Chaudhary R, Kubica J, Bliden K, Gurbel PA. Tantry U, et al. Expert Opin Pharmacother. 2018 Aug;19(12):1389-1398. doi: 10.1080/14656566.2018.1506767. Epub 2018 Aug 13. Expert Opin Pharmacother. 2018. PMID: 30102083 Review.
The authors also describe the pharmacologic effects of cangrelor and its pharmacologic interaction with other P2Y(12) receptor inhibitors. Finally, the authors discuss the large-scale clinical trials that compared the efficacy and safety of cangrelor with clopidogre …
The authors also describe the pharmacologic effects of cangrelor and its pharmacologic interaction with other P2Y(12) receptor inhibi …
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
Alexopoulos D, Pappas C, Sfantou D, Lekakis J. Alexopoulos D, et al. J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):13-22. doi: 10.1177/1074248417715004. Epub 2017 Jun 15. J Cardiovasc Pharmacol Ther. 2018. PMID: 29228817 Review.
Cangrelor is an intravenously administered P2Y(12) receptor antagonist with very fast, potent, and quickly reversible action. ...Accruing real-life experience is expected to improve our understanding of cangrelor's role in everyday clinical practice....
Cangrelor is an intravenously administered P2Y(12) receptor antagonist with very fast, potent, and quickly reversible action. ...Accr …
Cangrelor: A Review in Percutaneous Coronary Intervention.
Keating GM. Keating GM. Drugs. 2015 Aug;75(12):1425-34. doi: 10.1007/s40265-015-0445-3. Drugs. 2015. PMID: 26201463 Review.
Cangrelor (Kengrexal(), Kengreal()) is an intravenously administered P2Y12 receptor inhibitor. ...In conclusion, intravenous cangrelor is an important new option for use in patients undergoing PCI who have not been treated with oral P2Y12 inhibitors....
Cangrelor (Kengrexal(), Kengreal()) is an intravenously administered P2Y12 receptor inhibitor. ...In conclusion, intravenous cangr …
Cangrelor for treatment of arterial thrombosis.
Walsh JA 3rd, Price MJ. Walsh JA 3rd, et al. Expert Opin Pharmacother. 2014 Mar;15(4):565-72. doi: 10.1517/14656566.2014.882319. Epub 2014 Jan 30. Expert Opin Pharmacother. 2014. PMID: 24479981 Review.
A recent, Phase III randomized clinical trial of PCI patients demonstrated that cangrelor bolus and infusion reduced ischemic events compared with conventional clopidogrel therapy without increasing major bleeding. AREAS COVERED: This review outlines the pharmacodynamics, …
A recent, Phase III randomized clinical trial of PCI patients demonstrated that cangrelor bolus and infusion reduced ischemic events …
What is the Role of Cangrelor in Patients Undergoing PCI?
Droppa M, Geisler T. Droppa M, et al. Curr Vasc Pharmacol. 2018;16(5):484-489. doi: 10.2174/1570161116666180117105834. Curr Vasc Pharmacol. 2018. PMID: 29345586 Review.
However, oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naive patients. Cangrelor is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate antiplatelet inhibition during PCI …
However, oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naive patients. Cangrel …
467 results